Table 2.
Effect of IA thrombolysis on end points from all 15 trials
| End points | No. of trials | Active, n/N (%) | Control, n/N (%) | Pooled OR (95% CI) | P value | Test for publication bias (Begg’s test) | NNT or NNH |
|---|---|---|---|---|---|---|---|
| mRS 0-2 | 13 | 657/1,517 (43.3) | 402/1,261 (31.9) | 1.79 (1.34, 2.40) | < 0.001 | 0.8072 | 9 |
| mRS 0-1 | 13 | 435/1,530 (28.4) | 245/1,261 (19.4) | 1.81 (1.34, 2.44) | < 0.001 | 0.7143 | 11 |
| mRS 0-3 | 13 | 907/1,516 (59.8) | 617/1,280 (48.2) | 1.66 (1.25, 2.22) | 0.001 | 0.6255 | 9 |
| Good NIHSS outcome | 5 | 156/392 (39.7) | 68/299 (22.7) | 3.11 (2.14, 4.53) | < 0.001 | 0.6242 | 6 |
| Good BI outcome | 7 | 334/677 (49.3) | 190/622 (30.5) | 2.24 (1.78, 2.82) | < 0.001 | 0.8806 | 5 |
| mAOL, TIMI, or TICI 2-3 | 6 | 429/568 (75.6) | 227/489 (46.4) | 4.50 (1.97, 10.27) | < 0.001 | 0.5730 | 3 |
| mAOL, TIMI, or TICI 3 | 3 | 167/321 (51.9) | 71/271 (26.2) | 6.21 (4.05, 9.50) | < 0.001 | 0.6015 | 4 |
| Any ICH | 10 | 341/1,053 (32.4) | 150/770 (19.5) | 1.93 (1.37, 2.72) | < 0.001 | 0.9287 | 8 |
| Symptomatic ICH | 15 | 90/1,562 (5.8) | 61/1,318 (4.6) | 1.19 (0.83, 1.69) | 0.345 | 0.8695 | 88 |
| mRS 5-6 | 12 | 366/1,504 (24.3) | 365/1,251 (29.2) | 0.77 (0.61, 0.97) | 0.025 | 0.7839 | 21 |
| Mortality | 15 | 273/1,555 (17.6) | 254/1,312 (19.4) | 0.87 (0.71, 1.05) | 0.151 | 0.6560 | 55 |
n/N: number of patients achieving each end point/number of patients included. OR, odds ratio; NNT, number needed to treat; NNH, number needed to harm; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; mAOL, modified arterial occlusive lesion; TIMI, Thrombolysis in Myocardial Infarction; TICI, Thrombolysis in Cerebral Infarction; ICH, intracerebral hemorrhage.